SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
RMTI

Rockwell Medical, Inc. (NASDAQ:RMTI)

US · Delayed Price · Currency is USD
Healthcare · Drug Manufacturers - Specialty & Generic
$5.82-$0.44 (-7.03%)
 
Market cap
$23.1M
Insider Score
Health Score
Analyst consensus
Listed since
Jan 27, 1998
Market Cap$23.12M-36.1%
Revenue (ttm)$72.58M-4.0%
Net Income-$5.66M-2.5%
EPS-$1.48+8.1%
Shares Out3.97M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume51,381
Open$6.01
Previous Close$6.26
Day's Range$5.81 - $6.29
52-Week Range$4.89 - $12.90
Beta1.73
AnalystsBuy
Price Target$20.00(+243.64%)
Earnings DateMar 25, 2027
-5.75% (1D)
No price history available.

About RMTI

Rockwell Medical, Inc., together with its associated companies, operates as a biopharmaceutical firm specializing in treatments for chronic and end-stage kidney disease. The company provides a range of therapies and products aimed at addressing iron deficiency and supporting hemodialysis procedures, serving markets both within the United States and internationally. A key offering includes its Triferic line (Triferic Dialysate and Triferic AVNU), an innovative iron replacement therapy. This therapy is designed to replenish iron and maintain healthy hemoglobin levels in dialysis patients, notably without increasing existing iron stores. Beyond iron management, Rockwell Medical manufactures, sells, and distributes a comprehensive range of hemodialysis concentrates. These include various acid concentrates such as CitraPure (citric), Dri-Sate (dry), and RenalPure (liquid), alongside a dry acid concentrate mixer, and powder bicarbonate concentrates like RenalPure and SteriLyte. These crucial products are vital for sustaining life in dialysis patients by facilitating the removal of toxins and the replacement of essential nutrients in their bloodstream. The company further supplies ancillary items critical for hemodialysis procedures. This extensive catalog comprises blood tubing, fistula needles, dialyzers, pharmaceuticals, specialized component kits, dressings, cleaning agents, filtration salts, and other necessary provisions utilized by hemodialysis providers. Looking to the future, Rockwell Medical is actively developing additional therapeutic candidates. These include treatments for hospitalized individuals suffering from acute heart failure, as well as solutions for home infusion therapy, enabling patients to receive intravenous medications in a home setting. The company primarily serves medium and small-sized dialysis chains, as well as independent dialysis centers. Established in 1996, Rockwell Medical, Inc. maintains its corporate headquarters in Wixom, Michigan.

Address
30142 South Wixom road, Wixom, MI, 48393, US
Market Cap
23 million
Employees
157
Industrial Classification
Drug Manufacturers - Specialty & Generic

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$15.98K
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
1 Buy0 Hold0 SellAvg target $2.00 (-65.6%)

1 firm rating RMTI in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Sound
From RMTI’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-7.03%
5 Days
-15.04%
1 Month
-17.56%
6 Months
-26.61%
1 Year
-36.11%

$RMTI stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in RMTI holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by RMTI's directors and management

Net Shares Purchased by Insiders−6k−3k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

RMTI Estimated quarterly lobbying spending

Source: U.S. Senate LDA

RMTI Revenue by Segment or Geography

$30.72MTotal
Revenue recorded$19.12M62.25%
Accounts receivable, net$9.80M31.89%
Customer A$1.40M4.56%
Products Purchase Agreement$400.00K1.30%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New RMTI patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to RMTI from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in RMTI

VTIVanguard Morningstar Total Stock Market ETF$470.71K
VXFVanguard Extended Market ETF$253.92K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from RMTI’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
72

News check: Q3 earnings beat on revenue with 20% sales growth; loss reported but top-line expectations exceeded, suggesting operational momentum.

Recent Insider Activity

Buys
0
Sells
4
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.